Advertisement
U.S. markets close in 5 hours 21 minutes

CV Sciences, Inc. (CVSI)

Other OTC - Other OTC Delayed Price. Currency in USD
0.0382-0.0008 (-2.13%)
As of 10:16AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0390
Open0.0395
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0356 - 0.0395
52 Week Range0.0300 - 0.0600
Volume96,095
Avg. Volume215,067
Market Cap6.168M
Beta (5Y Monthly)0.60
PE Ratio (TTM)3.82
EPS (TTM)0.0100
Earnings DateMar 28, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for CVSI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CV SCIENCES INC
    Analyst Report: Exact Sciences CorporationExact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
    Rating
    Fair Value
    Economic Moat
    yesterdayMorningstar
View more
  • PR Newswire

    CV Sciences, Inc. Reports Fiscal Year-End 2023 Financial Results

    CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the year and quarter ended December 31, 2023.

  • PR Newswire

    CV Sciences, Inc. Expands +PlusCBD Pet Product Offerings with the Launch of Pet Chews

    CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, proudly announces its latest innovation and product launch: a premier CBD chew tailored for pets, +PlusCBD™ Pet Hip and Joint Health Chews and +PlusCBD™ Pet Calming Care Chews. +PlusCBD™Pet wellness treats are crafted with the utmost care and supported by extensive research, and

  • PR Newswire

    CV SCIENCES, INC. TO ANNOUNCE YEAR END AND FOURTH QUARTER 2023 RESULTS ON MARCH 28, 2024

    CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in nutraceuticals and plant-based foods, today announced that it will release financial results for the year and fourth quarter ended December 31, 2023, before the stock market opens on Thursday, March 28, 2024. The Company will hold a conference call with the investment community at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) that same day.